计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| O413886-5mg |
5mg |
期货 ![]() |
| |
| O413886-10mg |
10mg |
现货 ![]() |
| |
| O413886-25mg |
25mg |
期货 ![]() |
| |
| O413886-50mg |
50mg |
现货 ![]() |
| |
| O413886-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | HY-12288 | 5-[3-[(1~{S})-1-(2-hydroxyethylamino)-2,3-dihydro-1~{H}-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxy-benzenecarbonitrile | D10968 | DTXSID501026488 | Ozanimod [USAN:INN] | RPC1063:RPC-1063 | DB12612 | L04AA38 | AMY3373 | EX-A1316 | 5-{3-[ |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Ozanimod (RPC1063) |
| 生化机理 | Ozanimod(RPC1063)是一种选择性口服 S1P 受体 1 调节剂。第 3 阶段 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激动剂 |
| 作用机制 | S1P 1 受体激动剂;S1P 2 受体激动剂;S1P 3 受体激动剂;S1P 4 受体激动剂;S1P 5 受体激动剂 |
| 产品介绍 |
Information Ozanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3. Targets S1P1R (Cell-free assay); S1P5R (Cell-free assay) 0.41 nM(EC50); 11 nM(EC50) In vitro In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. In vivo Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses clinical symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits clinical and histological disease scores. In a Naïve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. |
| ALogP | 3.291 |
|---|---|
| HBD Count | 2 |
| Rotatable Bond | 7 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504771077 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile |
| INCHI | InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1 |
| InChi Key | XRVDGNKRPOAQTN-FQEVSTJZSA-N |
| Canonical SMILES | CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N |
| Isomeric SMILES | CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N |
| PubChem CID | 52938427 |
| 分子量 | 404.46 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 81 mg/mL (200.26 mM); Ethanol: 10 mg/mL (24.72 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 81 |
| DMSO(mM) Max Solubility | 200.2670227 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 404.500 g/mol |
| XLogP3 | 3.100 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 404.185 Da |
| 单同位素质量Monoisotopic Mass | 404.185 Da |
| 拓扑极表面积Topological Polar Surface Area | 104.000 Ų |
| 重原子数Heavy Atom Count | 30 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 609.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC area) | 98-100(%) |
|---|---|
| NMR Spectrum 1H | Conforms to structure |
| 1. Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H et al.. (2016) Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.. Br J Pharmacol, 173 (11): (1778-92). [PMID:26990079] |
| 2. Taylor Meadows KR, Steinberg MW, Clemons B, Stokes ME, Opiteck GJ, Peach R, Scott FL. (2018) Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.. PLoS ONE, 13 (4): (e0193236). [PMID:29608575] |
| 3. Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. (2020) Advances in oral immunomodulating therapies in relapsing multiple sclerosis.. Lancet Neurol, 19 (4): (336-347). [PMID:32059809] |
| 4. Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. (2020) Modulation of sphingosine-1-phosphate in ulcerative colitis.. Expert Opin Biol Ther, 20 (4): (413-420). [PMID:32093531] |